Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP749139.RAzLuaPWN30PP_buBa3MQT-s-2xJT2zK5IgTqTYSRc_ns130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP749139.RAzLuaPWN30PP_buBa3MQT-s-2xJT2zK5IgTqTYSRc_ns130_assertion type Assertion NP749139.RAzLuaPWN30PP_buBa3MQT-s-2xJT2zK5IgTqTYSRc_ns130_head.
- NP749139.RAzLuaPWN30PP_buBa3MQT-s-2xJT2zK5IgTqTYSRc_ns130_assertion description "[Topoisomerase II (TOP2) targeting drugs like doxorubicin and etoposide are frontline chemotherapeutics for a wide variety of solid and hematological malignancies, including breast and ovarian adenocarcinomas, lung cancers, soft tissue sarcomas, leukemias and lymphomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP749139.RAzLuaPWN30PP_buBa3MQT-s-2xJT2zK5IgTqTYSRc_ns130_provenance.
- NP749139.RAzLuaPWN30PP_buBa3MQT-s-2xJT2zK5IgTqTYSRc_ns130_assertion evidence source_evidence_literature NP749139.RAzLuaPWN30PP_buBa3MQT-s-2xJT2zK5IgTqTYSRc_ns130_provenance.
- NP749139.RAzLuaPWN30PP_buBa3MQT-s-2xJT2zK5IgTqTYSRc_ns130_assertion SIO_000772 22900064 NP749139.RAzLuaPWN30PP_buBa3MQT-s-2xJT2zK5IgTqTYSRc_ns130_provenance.
- NP749139.RAzLuaPWN30PP_buBa3MQT-s-2xJT2zK5IgTqTYSRc_ns130_assertion wasDerivedFrom befree-20150227 NP749139.RAzLuaPWN30PP_buBa3MQT-s-2xJT2zK5IgTqTYSRc_ns130_provenance.
- NP749139.RAzLuaPWN30PP_buBa3MQT-s-2xJT2zK5IgTqTYSRc_ns130_assertion wasGeneratedBy ECO_0000203 NP749139.RAzLuaPWN30PP_buBa3MQT-s-2xJT2zK5IgTqTYSRc_ns130_provenance.